EC Number | Application | Comment | Organism |
---|---|---|---|
2.3.1.26 | medicine | ACAT is a key enzyme in controlling cholesterol metabolism and represents a promising target for the development of therapeutic agents and inhibitors to control hypercholesterolemia, atherosclerosis and Alzheimer's disease | Mammalia |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.3.1.26 | (1R,3R,7R)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one | 45% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | |
2.3.1.26 | (1R,3R,7S)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one | 66% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | |
2.3.1.26 | (1R,3R,7S)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one | 0.01 mM, 66% inhibition | Oryctolagus cuniculus | |
2.3.1.26 | (1S)-1-[(1R,3R,5R)-3,5-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]hept-1-yl]propan-1-ol | 0.01 mM, 45% inhibition | Oryctolagus cuniculus | |
2.3.1.26 | (3R,5R,7R,8S)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1S)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one | 0.01 mM, 23% inhibition | Oryctolagus cuniculus | |
2.3.1.26 | (3R,5S,7S,8R)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1R)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one | 27% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | |
2.3.1.26 | (3S,4S)-3-[(1R,2R)-2-azido-1-hydroxybutyl]-3-bromo-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one | 65% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | |
2.3.1.26 | (3S,4S)-3-[(1S,2S)-2-azido-1-hydroxybutyl]-3-bromo-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one | 60% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | |
2.3.1.26 | (3S,5R,7R,8S)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1S)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one | 0.01 mM, 27% inhibition | Oryctolagus cuniculus | |
2.3.1.26 | (3S,5S,7S,8R)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1R)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one | 23% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | |
2.3.1.26 | (4S)-3-[(1R,2S)-2-azido-1-hydroxybutyl]-3-[(R)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one | 0.01 mM, 87% inhibition | Oryctolagus cuniculus | |
2.3.1.26 | (4S)-3-[(1R,2S)-2-azido-1-hydroxybutyl]-3-[(S)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one | 87% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | |
2.3.1.26 | (4S)-3-[(1S,2R)-2-azido-1-hydroxybutyl]-3-[(R)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one | 79% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | |
2.3.1.26 | (4S)-3-[(1S,2R)-2-azido-1-hydroxybutyl]-3-[(S)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one | 0.01 mM, 79% inhibition | Oryctolagus cuniculus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.1.26 | acyl-CoA + cholesterol | Mammalia | - |
CoA + cholesterol ester | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.3.1.26 | Mammalia | - |
- |
- |
2.3.1.26 | Oryctolagus cuniculus | - |
- |
- |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.3.1.26 | acyl-CoA + cholesterol | - |
Mammalia | CoA + cholesterol ester | - |
? | |
2.3.1.26 | palmitoyl-CoA + cholesterol | - |
Oryctolagus cuniculus | CoA + cholesteryl palmitate | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.3.1.26 | ACAT | two isoforms, ACAT1 and ACAT2 | Mammalia |
2.3.1.26 | acyl-CoA cholesterol O-acyltransferase | - |
Mammalia |
2.3.1.26 | acyl-CoA:cholesterol acyltransferase | - |
Mammalia |
EC Number | IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|---|
2.3.1.26 | additional information | - |
23% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | (3S,5S,7S,8R)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1R)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one | |
2.3.1.26 | additional information | - |
27% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | (3R,5S,7S,8R)-7-ethyl-8-hydroxy-3,5-diphenyl-2-[(1R)-1-phenylethyl]-6-oxa-2-azaspiro[3.4]octan-1-one | |
2.3.1.26 | additional information | - |
45% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | (1R,3R,7R)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one | |
2.3.1.26 | additional information | - |
60% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | (3S,4S)-3-[(1S,2S)-2-azido-1-hydroxybutyl]-3-bromo-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one | |
2.3.1.26 | additional information | - |
65% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | (3S,4S)-3-[(1R,2R)-2-azido-1-hydroxybutyl]-3-bromo-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one | |
2.3.1.26 | additional information | - |
66% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | (1R,3R,7S)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one | |
2.3.1.26 | additional information | - |
79% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | (4S)-3-[(1S,2R)-2-azido-1-hydroxybutyl]-3-[(R)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one | |
2.3.1.26 | additional information | - |
87% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested | Mammalia | (4S)-3-[(1R,2S)-2-azido-1-hydroxybutyl]-3-[(S)-hydroxy(phenyl)methyl]-4-phenyl-1-[(1S)-1-phenylethyl]azetidin-2-one |